RAMSAY HEALTH CARE LIMITED (RHC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RHC - RAMSAY HEALTH CARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.42
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Founded in Sydney in 1964, Ramsay Health Care is the largest provider of private healthcare in Australia, with operations in the UK, France, Indonesia and Malaysia. The company specialises in surgery, rehabilitation and psychiatric care. It was first listed in 1997.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$37.75

21 Nov
2024

-0.340

OPEN

$38.12

-0.89%

HIGH

$38.13

487,914

LOW

$37.40

TARGET
$44.004 16.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
RHC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 381.6 131.3 xxx
DPS (cps) xxx 80.0 82.3 xxx
EPS Growth xxx 100.0% - 65.6% xxx
DPS Growth xxx 6.7% 2.9% xxx
PE Ratio xxx N/A 29.3 xxx
Dividend Yield xxx N/A 2.1% xxx
Div Pay Ratio(%) xxx 21.0% 62.7% xxx

Dividend yield today if purchased 3 years ago: 1.19%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.12

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 11/03 - ex-div 40c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx381.6
DPS All xxxxxxxxxxxxxxx80.0
Sales/Revenue xxxxxxxxxxxxxxx16,665.4 M
Book Value Per Share xxxxxxxxxxxxxxx2,030.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,302.0 M
Net Profit Margin xxxxxxxxxxxxxxx1.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx5.94 %
Return on Invested Capital xxxxxxxxxxxxxxx1.76 %
Return on Assets xxxxxxxxxxxxxxx1.27 %
Return on Equity xxxxxxxxxxxxxxx5.98 %
Return on Total Capital xxxxxxxxxxxxxxx5.65 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx413.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx606 M
Long Term Debt xxxxxxxxxxxxxxx10,332 M
Total Debt xxxxxxxxxxxxxxx10,938 M
Goodwill - Gross xxxxxxxxxxxxxxx5,745 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx662 M
Price To Book Value xxxxxxxxxxxxxxx2.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx753.8 M
Capex % of Sales xxxxxxxxxxxxxxx4.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx15,055 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx674 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx112 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

25/10/2024

3

Neutral

$45.10

19.47%

UBS analysts had joined in on Ramsay Health Care's investor tours in Perth, showcasing Joondalup Health Campus and Hollywood Private Hospital.

As per the broker's report, the private hospitals operator signed a long-term public sector partnership for Joondalup, extending through 2048.

UBS noted a renewed focus on Emergency Departments as a key part of Ramsay's strategy to recover margins in its Australian operations, with increased patient acuity observed.

The broker highlighted ongoing negotiations with payors over reimbursement. Neutral rating retained with a price target of $45.10. No material updates were made to financial forecasts.

FORECAST
UBS forecasts a full year FY25 dividend of 76.00 cents and EPS of 117.00 cents.
UBS forecasts a full year FY26 dividend of 100.00 cents and EPS of 153.00 cents.

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

21/11/2024

3

Neutral

$48.22

27.74%

Ramsay Health Care has received an update from the NHS in the UK, revising the tariff payment for April 2024 to March 2025 to 3.9% from 0.6%, with the increase back-paid to 1 April and included in Ramsay's 1H results, notes Jarden.

The broker explains these payments will help offset inflationary pressures and improve the earnings outlook for the company’s UK operations.

Jarden highlights risks to UK funding beyond 1H25 and ongoing EBA pressures in Australia, maintaining its Neutral rating and $48.22 target price.

FORECAST
Jarden forecasts a full year FY25 dividend of 76.90 cents and EPS of 127.90 cents.
Jarden forecasts a full year FY26 dividend of 114.50 cents and EPS of 190.40 cents.
Access Extra Coverage Research History >

RHC STOCK CHART

FNArena News on RHC

1
Australian Broker Call *Extra* Edition – Nov 21, 2024

Nov 21 2024 - Daily Market Reports
2
In Brief: Collins Food, Domino’s, Guzman y Gomez & Artrya

Oct 04 2024 - Weekly Reports
3
September In Review: Banks versus Miners

Oct 03 2024 - Australia
4
Next Week At A Glance – 23-27 Sep 2024

Sep 20 2024 - Weekly Reports
5
Rudi’s View: Defensives, Healthcare, Resources & Data Centres

Sep 19 2024 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia